clinical trial · NCT07933133
A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary Fibrosis
CSPC-NBP Pharmaceutical Co., Ltd.·phase2·not yet recruiting·n = 300
Idiopathic Pulmonary FibrosisSYH9061PlaceboOfev®
brief summary
This is a multicenter, randomized, blinded, placebo- and active-controlled Phase II study to evaluate the efficacy, safety, and pharmacokinetic (PK) profile of SYH9061 at different doses and dosing frequencies in patients with IPF, and to determine the optimal recommended dose for Phase III confirmatory studies.
started
Dec 1, 2026
primary completion
Apr 1, 2029
completion
Feb 1, 2030
last updated
Nov 12, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol